Blog

Asymmetry Finance

Asymmetry Finance is an innovative synthetic dollar protocol, delivering a yield-bearing stablecoin that aims to be both inflation-resistant and scalable enough to meet the demands of an exponentially growing market.

Amber Therapeutics

Amber Therapeutics is developing Amber-UI, a breakthrough adaptive neuromodulation therapy to treat women suffering with mixed urinary incontinence with the hope of transforming the clinical outcome and quality of life of a large untreated population. Amber-UI runs on the Company’s fully implantable Picostim system that targets the pudendal nerve to both stimulate and sense physiological responses. The therapy is configurable to the individual’s need and can respond dynamically to different events, adapting as needed between modes of operation. Amber’s technology platform is highly versatile and can be used to explore other novel therapy applications in both the pelvis and the broader nervous system, demonstrated by the work being carried out by the Company’s academic partnerships.

T-Therapeutics

T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge. The company was created to harness the power of T cell biology, evolved over millions of years, to create safe and effective treatments for many cancers and autoimmune diseases.

Tenpoint Therapeutics

Tenpoint Therapeutics™ is pioneering a new treatment for presbyopia, BRIMOCHOL™ PF, with a PDUFA date from US FDA of January 28, 2026. The company also has a R&D pipeline of novel therapies for other unmet needs in ophthalmology.

ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). ARTBIO’s approach uses the optimal alpha-emitting isotope (Pb212) with tumor-specific targets to create unique radioligand therapeutics. The company’s AlphaDirectTM technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.

Shift Bioscience

Shift Bioscience (Shift) is a Cambridge, UK-based biotechnology company focused on safe cellular reprogramming for rejuvenation. The company leverages a proprietary cellular age clock and an active machine learning approach to discover novel factors for safer cellular rejuvenation without the use of pluripotency-inducing reprogramming genes. Shift aims to enable the development of reprogramming-based therapeutics to prevent and treat age-associated diseases.

CHARM Therapeutics

CHARM Therapeutics is a 3D deep-learning research Company discovering and developing transformational medicines. Based on the award-winning discoveries of David Baker in protein-folding, CHARM has developed a proprietary technology based on the first rapid, accurate protein/ligand co-folding algorithm. The Company’s mission is to use these insights to address challenging targets in cancer and other disease areas and discover and develop new drugs against these targets.

 

Eleos

Eleos is pioneering CareOps Automation. By consolidating the entire behavioral care workflow — everything from progress notes all the way to session intelligence— clinicians are freed from time-consuming operational burdens. Eleos takes care of CareOps, honing in on automating operational necessities, including all documentation, compliance administration as well as providing deep clinical insights through session intelligence. Eleos makes evidence-based behavioral care a reality so clinicians, providers, and networks can measurably and comparatively track treatment and progress.

AviadoBio

AviadoBio is a pioneering gene therapy company focused on developing and delivering transformative medicines for people living with neurodegenerative disorders.

Avivomed

Avivomed, is a medical device company developing innovative neuromodulation technology to treat large disease populations.